The DOI matches its Crossref record.
(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroprotectant Which Blocks N-Methyl-D-Aspartate Responses
Open accessAbstract
(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (20, CP-101,606) has been identified as a potent and selective N-methyl-D-aspartate (NMDA) antagonist through a structure activity relation (SAR) program based on ifenprodil, a known antihypertensive agent with NMDA antagonist activity. Sites on the threo-ifenprodil skeleton explored in this report include the pendent methyl group (H, methyl, and ethyl nearly equipotent; propyl much weaker), the spacer group connecting the C-4 phenyl group to the piperidine ring (an alternating potency pattern with 0 and 2 carbon atoms yielding the greatest potency), and simple phenyl substitution (little effect). While potent NMDA antagonists were obtained with a two atom spacer, this arrangement also increased alpha 1 adrenergic affinity. Introduction of a hydroxyl group into the C-4 position on these piperidine ring resulted in substantial reduction in alpha 1 adrenergic affinity. The combination of these observations was instrumental in the discovery of 20. This compound potently protects cultured hippocampal neurons from glutamate toxicity (IC50 = 10 nM) while possessing little of the undesired alpha 1 adrenergic affinity (IC50 approximately 20 microM) of ifenprodil. Furthermore, 20 appears to lack the psychomotor stimulant effects of nonselective competitive and channel-blocking NMDA antagonists. Thus, 20 shows great promise as a neuroprotective agent and may lack the side effects of compounds currently in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
NMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Ionotropic and metabotropic glutamate receptor structure and pharmacology
Kew, J. N. C., & Kemp, J. A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2200-z · Cited by 788
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
The Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535
Philpot, B. D., Sekhar, A. K., Shouval, H. Z., & Bear, M. F. (2001) · Neuron · doi:10.1016/s0896-6273(01)00187-8 · Cited by 414
Mony, L., Kew, J. N., Gunthorpe, M. J., & Paoletti, P. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00304.x · Cited by 401
Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons
Stocca, G., & Vicini, S. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.013bu.x · Cited by 363
Boyce, S., Wyatt, A., Webb, J. K., O’Donnell, R., Mason, G., Rigby, M., Sirinathsinghji, D., Hill, R. G., & Rupniak, N. M. J. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00218-4 · Cited by 342
Ion Channels as Therapeutic Targets: A Drug Discovery Perspective
Bagal, S. K., Brown, A. D., Cox, P. J., Omoto, K., Owen, R. M., Pryde, D. C., Sidders, B., Skerratt, S. E., Stevens, E. B., Storer, R. I., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3011433 · Cited by 316
Neuronal Death Mechanisms and Therapeutic Strategy in Ischemic Stroke
Mao, R., Zong, N., Hu, Y., Chen, Y., & Xu, Y. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00859-0 · Cited by 273
G. Moloney, M. (1998) · Natural Product Reports · doi:10.1039/a815205y · Cited by 255
Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism
Nutt, J. G., Gunzler, S. A., Kirchhoff, T., Hogarth, P., Weaver, J. L., Krams, M., Jamerson, B., Menniti, F. S., & Landen, J. W. (2008) · Movement Disorders · doi:10.1002/mds.22169 · Cited by 133
Reversible Control of Native GluN2B-Containing NMDA Receptors with Visible Light
Geoffroy, C., Berraud-Pache, R., Chéron, N., McCort-Tranchepain, I., Doria, J., Paoletti, P., & Mony, L. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00247 · Cited by 9
Metadata
- Authors
- Chenard, B. L., Bordner, J., Butler, T. W., Chambers, L. K., Collins, M. A., De Costa, D. L., Ducat, M. F., Dumont, M. L., & Fox, C. B.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-08
- Volume
- 38
- Issue
- 16
- Pages
- 3138-3145
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2949574343
- Cited by
- 180
- References
- 0
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.